Loading
Natera's tumour gene test, which reads every gene's DNA and RNA and can be ordered on the same sample as its Signatera blood test for recurrence.
Altera is Natera's comprehensive genomic profiling test. Whole-exome DNA sequencing across about 20,000 genes reports single-nucleotide variants, insertions and deletions, copy number changes and selected rearrangements, with microsatellite instability and tumour mutational burden; whole-transcriptome RNA sequencing adds fusions and transcripts such as AR-V7, EGFR vIII and MET exon 14 skipping; and PD-L1 (22C3) and HER2 immunohistochemistry are included automatically. One tumour sample can be used for both Altera and Signatera, Natera's residual disease blood test. Natera states that its tests were developed by its CLIA-certified laboratory and have not been cleared or approved by the FDA.
Whole-exome DNA sequencing of about 20,000 genes and whole-transcriptome RNA sequencing of the tumour, with PD-L1 (22C3) and HER2 immunohistochemistry included automatically.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Altera" OR ABSTRACT:"Altera" OR TITLE:"Natera Altera" OR ABSTRACT:"Natera Altera") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Altera, not a curated reading list.
Shares AR-V7 splice variant, TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Whole-exome & whole-genome sequencing and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Next-generation sequencing (NGS), RNA sequencing & expression profiling and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/